The Michael J. Fox Foundation Expands Landmark Parkinson's Research Study toward Better Treatments and Prevention
Now offering additional ways to participate, PPMI has lowered its screening age eligibility and is remotely screening individuals aged 40 or older without PD and people with PD diagnosed within the last seven years for potential longitudinal enrollment at one of 50 sites in 12 countries. Additionally, anyone aged 18 or older in the United States can contribute data on health and wellbeing through the newly relaunched myPPMI study participant platform. This expansion builds on PPMI's longstanding commitment to drive and deepen understanding of the biological fingerprint and clinical footprint of Parkinson's disease.
'Since PPMI began, the study has risen to meet current scientific needs while looking forward to anticipate the infrastructure and novel data required for future research. Partnering with more participants, in the clinics and online, offers new opportunities to develop more tools and learnings to speed therapies while also engaging a broader audience of potential volunteers for the clinical trials to come,' said PPMI's principal investigator and distinguished scientist at the Institute for Neurodegenerative Disorders, Kenneth Marek, MD.
PPMI's latest expansion comes as The Michael J. Fox Foundation recognizes extraordinary research progress and an innovative high-risk, high-reward model that has generated more than $2.5 billion dollars to support global research programs. The unprecedented opportunity to speed cures is matched only by the urgency of the need: PD is now the second most common and fastest-growing neurological disease in the world. An estimated 6 million or more people around the world, including over 1 million Americans, live with Parkinson's today. With no way to prevent, stop or slow the disease, PD is projected to double globally by 2040.
Expanded Eligibility for In-Clinic Study Population Aims to Answer Key Questions
In 2023, PPMI data validated a biomarker test for a key Parkinson's pathology — the aggregation of the protein alpha-synuclein. This groundbreaking new test, the alpha-synuclein seed amplification assay (a-syn SAA), allowed scientists, for the first time, to detect this Parkinson's pathology in living people. The results from PPMI data analysis showed remarkable findings. Firstly, the a-syn SAA test was positive in many people aged 60 or older who were not yet diagnosed with clinical PD and correlated with severe smell loss (≥10% of expected smell ability controlled for age and sex). Six to ten percent of participants in the diagnosed PD cohort had a negative a-syn SAA result. This was most common in people with normal smell ability, and in individuals who carried a PD-associated mutation in the LRRK2 gene.
These findings have pointed to a deeper biological understanding of Parkinson's and have led PPMI to adjust its cohorts. Enrolling people aged 40 or older with smell loss and a-syn SAA positivity will allow scientists to study how early this pathology appears, which could help design prevention trials and further understand younger disease onset. PPMI will also further examine the biology of individuals later in disease with a Parkinson's diagnosis within the past seven years and robust smell ability, many presumably negative on the a-syn SAA, to understand the biological markers present in these individuals.
'In science, each answer begets more questions. PPMI is iterating to build on past success and drive to the next breakthrough. These quick pivots are possible only with the trust and commitment of the initiative's many partners. We are grateful for the efforts and contributions of the study team, the scientists, the sites and most importantly the study's generous volunteers who have helped change what we know about this disease and how research is moving to stop it,' said MJFF Chief Program Officer Sohini Chowdhury.
Eligible participants — over age 40 and not diagnosed with Parkinson's or over age 30 and diagnosed with Parkinson's in the past seven years — can request a smell test at www.mysmelltest.org/expansion.
Online Data Capture Complements In-Clinic Research to Elucidate Brain Health and Disease
PPMI has also updated its online experience for participants. In 2020, the study launched an English-language online platform to capture data on health and wellbeing over time from anyone aged 18 or older in the United States, with or without PD. To date, more than 46,000 participants have completed more than 222,000 online study visits, contributing data in over 3.3 million surveys. This data is pointing scientists to predictive features and varied progression profiles, which may help improve care and research practices.
The online capture part study has been folded into the myPPMI participant platform. Introduced in 2023, myPPMI provides opportunities for participants to contribute in varied ways to the initiative (e.g., online, in-person) and to contribute study data virtually and, in some cases, individuals' personal research information. In 2024, PPMI began offering access to personal data from the a-syn SAA test, dopamine transporter (DAT) brain imaging scan, and a physician assessment of movement issues. One of the first Parkinson's studies to share back this volume of research information directly to trial volunteers, PPMI provides education and counseling around these tests as well. myPPMI is available in the U.S., Austria, England, Canada, Germany, Spain, the Netherlands, with additional countries starting later in 2025; content is currently translated into German, Dutch and Spanish. The integration of online data collection into myPPMI enhances the participant experience as well as widens the pool of contributors.
'I am grateful for the opportunity to be part of this study community. Joining PPMI has been an empowering step in my Parkinson's journey, and I'm glad that the new platform will make it easy to contribute more to the study,' said PPMI Community Advisory Board member Marty Acevedo, 65, of Oceanside, California. 'Furthermore, I'm glad that the study is now returning some personal research information back to us participant partners. This knowledge on our own disease can help navigate care and research decisions.'
PPMI's Continuing Collaborations to Grow Study Impact
Today, MJFF is convening hundreds of academic, research and industry leaders from around the world for its PPMI Annual Investigators Meeting held in New York City. Hosted by MJFF, the annual meeting features reports on promising avenues of exploration in the study and advancements in our understanding around disease progression and biomarkers, while addressing challenges and opportunities in clinical trial innovations, including new approaches to integrating patient perspectives.
Heralded as 'the study that's changing everything' about how Parkinson's is diagnosed, managed and treated, PPMI and its data are made possible by the nearly 4,000 volunteers — people with PD, disease risk factors and control volunteers — at PPMI clinics and more than 45,000 in its online study. All de-identified data is shared in real-time with qualified scientists to speed scientific discovery and validation of findings toward broad application.
While iterating its current protocols, PPMI is also collaborating to grow the impact of its dataset, biosample library and engaged participant base.
PPMI is a $750-million public-private partnership. Major funding for PPMI comes from ASAP, a global research initiative focused on accelerating the pace of discovery for Parkinson's disease. ASAP support is enabling expanded PPMI recruitment efforts and remote testing as well as assay development efforts to enable breakthroughs such as αSyn-SAA. This infrastructure provides a ready platform for future discoveries.
In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation, Connie and Steven Ballmer, and Susan and Riley Bechtel. The study is additionally funded by a consortium of more than 40 biotech and pharmaceutical firms providing financial and in-kind support, and by tens of thousands of individual donors to The Michael J. Fox Foundation.
About The Michael J. Fox Foundation for Parkinson's Research (MJFF)
As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding $2.5 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; creates a robust open- access data set and biosample library to speed scientific breakthroughs and treatment with its landmark clinical study, PPMI; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at www.michaeljfox.org, Facebook, Instagram and LinkedIn.
View original content to download multimedia: https://www.prnewswire.com/news-releases/the-michael-j-fox-foundation-expands-landmark-parkinsons-research-study-toward-better-treatments-and-prevention-302441177.html
SOURCE The Michael J. Fox Foundation for Parkinson's Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
EBSCO Information Services Introduces Africa Studies Source to Expand Global Scholarly Impact
~ Extensive Collection of Full-text Magazines and Journals for Africa Studies ~ IPSWICH, Mass., July 17, 2025 /PRNewswire-PRWeb/ -- Researchers across the globe looking for an authoritative resource for Africa studies will benefit from the release of Africa Studies Source from EBSCO Information Services (EBSCO). Africa Studies Source includes a vast array of scholarly full-text journals and magazines, offering detailed insights into the history, culture, politics, education, and ongoing medical and scientific research that define the African continent. Africa Studies Source offers researchers access to more than 656 magazines and journals, including 614 peer-reviewed journals. Researchers gain valuable insights from international and regional journals, all authored by leading experts in various fields. The unique resource provides coverage of a wide array of subjects including the African diaspora, African history and politics, agriculture, business and industry, cultural traditions, colonialism & human rights, economic development & globalization, education, environmental issues, foreign relations, government & politics, health & medicine, religion, and science & technology. EBSCO Information Services Senior Vice President of Research Databases Sara Earley says the new resource empowers scholars to explore the evolving narratives shaping the continent of Africa. "By providing access to a vast collection of scholarly journals, the database supports the advancement of research on Africa. Africa Studies Source is invaluable for researchers seeking in-depth insights into the continent's ongoing developments." The launch of Africa Studies Source demonstrates EBSCO's ongoing dedication to advancing global academic research with the addition of another Cultural and Area Studies resource. For more information, visit: Africa Studies Source. About EBSCO Information Services EBSCO Information Services (EBSCO) is a leading provider of online research content and cutting-edge search technologies serving libraries, healthcare and medical institutions, corporations, and government agencies worldwide. As an AI-enabled services leader, EBSCO offers comprehensive solutions from research, acquisition management, subscription services and discovery services to clinical decision support and patient care, learning, and research and development, EBSCO provides institutions with access to content and resources to serve the information and workflow needs of their users and organizations. Our commitment to AI-driven innovation positions EBSCO at the forefront of the industry, enabling us to meet the evolving needs of the information services landscape. For more information, visit the EBSCO website at: Visit our blog at EBSCOpost or follow us on X, Facebook, LinkedIn and Instagram. For more information, please contact: Karena Donnelly Sr Communications Specialist kdonnelly@ Media Contact Karena Donnelly, EBSCO Information Services, 9783566500, kdonnelly@ View original content to download multimedia: SOURCE EBSCO Information Services Sign in to access your portfolio
Associated Press
5 hours ago
- Associated Press
Kyruus Health Expands Reach to Integrate with Bing and Other AI Experiences Consumers Use to Find Care
BOSTON, July 17, 2025 /PRNewswire/ -- Building on the successful launch of Reach in October 2024, Kyruus Health, the leading care access platform, today announced a significant expansion of the digital channels where it connects patients with care. With Reach, listings managed by Kyruus Health will display across Bing Places for Business, Google Business Profiles, and 100 health plan brand websites, enabling organizations to more effectively attract patients in today's evolving AI-powered search environment. The search landscape is undergoing a dramatic transformation. With Kyruus Health's Reach now covering over 90% of U.S. search engine traffic through strategic integrations, provider organizations can effectively meet people where they are. This comprehensive coverage, built on trusted provider data management and directly integrated into AI-powered tools like Google's AI Overviews and consumer platforms that incorporate Bing technology, Reach now addresses the main ways consumers search for care including ChatGPT and Launched to address the growing complexities of digital presence management for health systems, Reach has quickly proven its impact in ensuring accurate and consistent provider and location information is available wherever patients are searching for care. By leveraging the robust provider data management capabilities of Kyruus Connect, Reach streamlines the management and updates of digital listings, enabling accuracy and consistency across critical search and discovery platforms. As patients increasingly use diverse platforms and conversational AI interfaces, Reach ensures that accurate provider and location data is seamlessly fed to these major search engines and platforms. The data powers patient acquisition and caters to evolving search habits, ensuring healthcare organizations remain visible and accessible. Early adopters like Intermountain Health are already experiencing tangible results using Reach, reporting a 42% increase in appointments booked via Reach's integration with Google Reserve within the first two months of implementation. Health systems partnered with Kyruus Health on Reach saw clicks from Google driving over 20% conversion, compared to the average click rate on healthcare email marketing of 2.8%. 'Healthcare is unique, and ensuring that people find the care that they are searching for requires a nuanced approach. As GenAI transforms the digital landscape, our customers need to be everywhere patients are seeking information,' said Peter Boumenot, Chief Product Officer at Kyruus Health. 'Kyruus Health's Reach provides that comprehensive presence, ensuring accurate provider and location data fuels patient acquisition across channels like Google, Gemini, Bing, and ChatGPT, ultimately making it easier for people to connect with the right care.' Collectively, these Reach capabilities optimize patient acquisition and the overall digital journey. By ensuring that structured, accurate data fuels AI-driven search, enabling seamless online scheduling and boosting provider visibility, Reach delivers an enhanced and user-friendly patient experience right from their initial online interaction. Looking ahead, Kyruus Health will continue to build on its Reach solution with the fall launch of Reputation Management. Initial capabilities will include review monitoring, review response with a managed service option, bulk actions, and performance insights. This launch will set the stage for a subsequent release that will incorporate more advanced features, including AI-powered sentiment analysis and review generation. ABOUT KYRUUS HEALTH Kyruus Health is the leading care access platform on a mission to connect people to the right care. The company connects 425,000 providers across more than 1,000 hospitals and 500 medical groups, and more than 150 million health plan members across 100 health plan brands, so every stakeholder can access and harness the most accurate, comprehensive, and contextually relevant information. By enabling informed decisions and confident action, the care access platform supports healthier outcomes, reduces friction in healthcare, and grants more time back in everyone's day. To learn more, visit or follow us on LinkedIn. MEDIA CONTACT Ashley Dauwer Corporate Marketing and PR Manager, Kyruus Health [email protected] View original content to download multimedia: SOURCE Kyruus Health
Los Angeles Times
16 hours ago
- Los Angeles Times
Robert Fried Says Niagen Bioscience Has the Key to Better Aging, and He Has the Science to Prove It
In a recent interview, Robert Fried, CEO of Niagen Bioscience, delves into the science of aging and the pivotal role of a molecule known as NAD (nicotinamide adenine dinucleotide). He explains how NAD is crucial for cellular energy and repair, and how its decline with age contributes to a slower recovery from injuries and the progression of age-related conditions. Fried clarifies a common misconception: NAD itself is not bioavailable when taken orally. Instead, he highlights the importance of a precursor molecule, nicotinamide riboside, which is readily absorbed by cells and converted into NAD. Niagen Bioscience's flagship product, Niagen, is a patented and extensively researched form of nicotinamide riboside. A significant concern for Fried is the lack of integrity in the broader dietary supplement market. He cites a study where less than 1% of competing NAD-boosting products met their label claims, with 40% containing none of the active ingredient. He contrasts this with Niagen Bioscience's commitment to rigorous scientific research, evidenced by 38 peer-reviewed human clinical studies and over 100 preclinical studies. Fried emphasizes that Niagen Bioscience is not just another supplement company. They are singularly focused on NAD and its potential therapeutic benefits. A major four-and-a-half-year study on Parkinson's disease, involving 400 participants, is nearing completion and is expected to provide further evidence of Niagen's potential to address serious age-related diseases. The company's mission, according to Fried, is to educate the public about the importance of NAD and to establish Niagen as the 'gold standard' in the NAD space. He stresses that Niagen is the only patented, legal, and trusted form of nicotinamide riboside, backed by unparalleled scientific research.
